
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Gross Profit 2011-2026 | NVTA
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 98.7 M | 67.6 M | 18.1 M | -2.83 M | -8.14 M | -4.02 M | -519 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.7 M | -8.14 M | 24.1 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
388 M | $ 8.92 | 0.56 % | $ 594 M | ||
|
Brainsway Ltd.
BWAY
|
30.6 M | $ 13.76 | 0.81 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 26.01 | 0.68 % | $ 722 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
2.8 B | $ 68.2 | 2.8 % | $ 26.6 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 154.35 | 1.57 % | $ 7.65 B | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 17.52 | 1.18 % | $ 934 M | ||
|
Guardant Health
GH
|
144 M | $ 87.53 | 0.4 % | $ 11 B | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.26 B | $ 103.87 | 0.01 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 15.53 | 3.88 % | $ 470 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
18.5 M | $ 17.01 | -1.62 % | $ 2.21 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 99.43 | 1.86 % | $ 8.2 B | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 2.9 | 2.11 % | $ 94.1 K | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 168.32 | 2.14 % | $ 28.9 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 194.97 | 1.87 % | $ 139 B | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
2.86 B | $ 121.42 | 1.79 % | $ 19.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 199.2 | 0.13 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 113.43 | 1.43 % | $ 34.5 B | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.12 | 0.66 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
5.98 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
314 M | $ 8.36 | 1.46 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
421 M | $ 9.24 | 1.43 % | $ 2 B | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 78.46 | -0.05 % | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.41 | 3.31 % | $ 423 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
246 M | $ 452.71 | -0.21 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
2.39 B | $ 1 215.3 | 1.35 % | $ 25 B | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
81.5 M | $ 17.95 | 3.16 % | $ 402 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
127 M | $ 199.43 | 0.89 % | $ 19.6 B | ||
|
OPKO Health
OPK
|
219 M | $ 1.2 | 0.42 % | $ 833 M |